Table 1. Oligonucleotide therapeutic companies. Source: BCIQ: BioCentury Online Intelligence; company press releases and websites

Company

Modality

Stage of lead compound

Antisense Therapeutics Ltd. (ASX:ANP)

Antisense

Phase IIa complete

iCo Therapeutics Inc. (TSX-V:ICO)

Antisense

Phase II

Isarna Therapeutics GmbH

Antisense

Phase II

Isis Pharmaceuticals Inc. (NASDAQ:ISIS)

Antisense

Marketed

OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI)

Antisense

Phase III

Prosensa Holding N.V. (NASDAQ:RNA)

Antisense

Phase III

Santaris Pharma A/S

Antisense

Phase IA

Sarepta Therapeutics Inc. (NASDAQ:SRPT)

Antisense

Phase II

Xenon Pharmaceuticals Inc.

Antisense

Preclinical

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)

Small interfering RNA

Phase II

Arrowhead Research Corp. (NASDAQ:ARWR)

siRNA

Phase I

Benitec Biopharma Ltd. (ASX:BLT)

siRNA

Preclinical

Dicerna Pharmaceuticals Inc.

siRNA

Preclinical

Marina Biotech Inc. (OTCQX:MRNA)

siRNA

Phase I

ProNAi Therapeutics Inc.

siRNA

Phase II

RXi Pharmaceuticals Corp. (OTCQX:RXII)

siRNA

Phase I

SBI Biotech Co. Ltd.

siRNA

Phase II

Silence Therapeutics plc (LSE:SLN)

siRNA

Phase II

Sylentis S.A.

siRNA

Phase I

Tekmira Pharmaceuticals Corp. (TSX:TKM; NASDAQ:TKMR)

siRNA

Phase I

TransDerm Inc.

siRNA

Phase I

InteRNA Technologies B.V.

MicroRNA

Preclinical

miRagen Therapeutics Inc.

miRNA

Preclinical

Mirna Therapeutics Inc.

miRNA

Phase I

MiReven Pty Ltd.

miRNA

Preclinical

Regulus Therapeutics Inc. (NASDAQ:RGLS)

anti-miRNA

Preclinical

RXi Pharmaceuticals

Long noncoding RNA

Undisclosed

RaNA Therapeutics Inc.

lncRNA

Undisclosed

ASantaris' lead program is an anti-miRNA in Phase II.